The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 07, 2022
Filed:
Oct. 17, 2019
Applicant:
Fate Therapeutics, Inc., San Diego, CA (US);
Inventors:
Bahram Valamehr, San Diego, CA (US);
Ramzey Abujarour, San Diego, CA (US);
Tom Tong Lee, San Diego, CA (US);
Weijie Lan, San Diego, CA (US);
Raedun Clarke, San Diego, CA (US);
Ryan Bjordahl, San Diego, CA (US);
Assignee:
Fate Therapeutics, Inc., San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/074 (2010.01); C12N 15/90 (2006.01); C12N 5/0783 (2010.01); A61P 35/02 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); C12N 5/078 (2010.01); C12N 15/85 (2006.01); A61K 35/17 (2015.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
C12N 5/0696 (2013.01); A61K 35/17 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 14/7051 (2013.01); C07K 14/70503 (2013.01); C07K 16/2803 (2013.01); C12N 5/0634 (2013.01); C12N 5/0636 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); A61K 2035/124 (2013.01); C07K 2319/33 (2013.01); C12N 15/1138 (2013.01); C12N 15/90 (2013.01); C12N 2310/20 (2017.05); C12N 2501/25 (2013.01); C12N 2501/505 (2013.01); C12N 2501/51 (2013.01); C12N 2501/515 (2013.01); C12N 2501/599 (2013.01); C12N 2501/998 (2013.01); C12N 2506/03 (2013.01); C12N 2506/11 (2013.01); C12N 2510/00 (2013.01); C12N 2800/107 (2013.01); C12N 2800/80 (2013.01); C12N 2830/00 (2013.01);
Abstract
Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.